Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Stryker Corporation

SYK

Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, mechanical thrombectomy systems, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.

Last trade $315.72
Day change +$5.00 (+1.61%)
Day range $306.58 – $319.25
Volume 2,517,607
Market cap $118.29B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$118.29B
Price / earnings
32.65×
Price / book
5.04×
Price / sales
4.5×
EV / sales
4.94×
EV / EBITDA
18.72×

Profitability

Earnings per share
$9.52
Return on assets
7.67%
Return on equity
15.45%
Dividend yield
1.13%

Liquidity and leverage

Debt / equity
0.64×
Current ratio
2.18×
Quick ratio
1.3×
Cash ratio
0.5×

Cash flow

Price / cash flow
21.72×
Price / free cash flow
25.87×
Free cash flow
$4.57B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SYK, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$6.52B$6.59B$6.02B$7.17B$6.06B$6.02B$5.87B$6.44B
Cost of revenue$2.27B$2.09B$2.21B$2.54B$2.21B$2.18B$2.12B$2.26B
Gross profit$4.25B$4.5B$3.81B$4.63B$3.85B$3.84B$3.74B$4.17B
Selling, general and administrative$2.31B$2.23B$2.28B$2.23B$2.05B$2.08B$2.3B$2.12B
Research and development$433M$434M$413M$401M$410M$407M$405M$358M
Total operating expenses$3.21B$2.84B$2.87B$2.82B$2.72B$2.73B$2.91B$3.59B
Operating income$1.03B$1.66B$936M$1.8B$1.14B$1.11B$837M$581M
Interest expense-$143M-$141M-$148M-$607M-$157M-$159M-$137M-$409M
Income before taxes$997M$1.56B$850M$1.71B$1.03B$1.02B$764M$528M
Income taxes$244M$288M$105M$856M$170M$132M$110M-$18M
Net income$753M$1.28B$745M$849M$859M$884M$654M$546M
Net income attributable to common shareholders$753M$1.28B$745M$849M$859M$884M$654M$546M
EBITDA$1.62B$1.96B$1.24B$2.13B$1.52B$1.46B$1.14B$1.8B
Basic earnings per share$1.97$3.32$1.95$2.22$2.25$2.32$1.71$1.43
Diluted earnings per share$1.96$3.30$1.93$2.20$2.22$2.29$1.69$1.41

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Nerve Repair and Regeneration - Global Market Share Analysis, Industry Trends, Growth Forecasts, 2026-2031 | AI-Enabled Devices and Biomaterials Fuel 11.96% CAGR

The global nerve repair and regeneration market is projected to grow from USD 10.65 billion in 2025 to USD 20.97 billion by 2031, expanding at an 11.96% CAGR. Growth is driven by rising nerve injuries, advances in neurostimulation technologies, and biomaterial innovations. Neurostimulation devices currently dominate with 58.74% market share, while biomaterials are the fastest-growing segment at 14.01% CAGR. High implant costs and cybersecurity risks remain challenges, with Asia-Pacific expected to record the fastest regional growth.

Zacks Investment Research

ISRG EPS Climbs 25% to $3: Is Innovation Driving Profitable Growth?

Intuitive Surgical delivered robust Q3 2026 results with adjusted EPS up 25% to $3 and revenue growth of 22% to $3.1 billion, driven by expanding robotic platform adoption and improved operating efficiency. The company maintains a 42% operating margin while investing heavily in R&D for AI features and new platforms. However, reported GAAP net income declined due to a $450 million litigation settlement. Peer medical device makers Stryker and Medtronic also posted strong earnings growth, though facing headwinds from procedure volume pressures and supply constraints.

Zacks Investment Research

GEHC or SYK: Which Is the Better Value Stock Right Now?

In a comparison of two Medical-Products sector stocks, GE HealthCare Technologies (GEHC) emerges as the better value option compared to Stryker (SYK). GEHC has a Zacks Rank of #2 (Buy) with stronger earnings estimate revisions, a lower forward P/E ratio of 16.53 versus SYK's 20.86, and a superior Value grade of B compared to SYK's D grade. GEHC also shows better valuation metrics across PEG and P/B ratios.

Zacks Investment Research

Are Options Traders Betting on a Big Move in Stryker Stock?

Stryker Corporation (SYK) is experiencing elevated implied volatility in its options market, particularly in December 2026 put options. However, the fundamental outlook appears weak, with the company holding a Zacks Rank #4 (Sell) rating and six analysts downgrading earnings estimates for the current quarter, reducing consensus estimates from $5.10 to $5.03 per share.

The Motley Fool

Medtronic Just Retired 55 Million Shares Without Spending Cash. Is the Stock a Buy?

Medtronic completed a spinoff of its diabetes segment (MiniMed) and retired 55 million shares without cash expenditure, which will boost future EPS. The company reported strong Q1 FY2027 results with 14% revenue growth and is approaching Dividend King status (49 consecutive years of increases). Despite operational improvements and a reinvigorated pipeline with 50+ FDA approvals, Medtronic trades at a discount to medtech peers.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Sep 30, 2026$0.88Oct 30, 2026recurring
Jun 30, 2026$0.88Jul 31, 2026recurring
Mar 31, 2026$0.88Apr 30, 2026recurring
Dec 31, 2025$0.88Jan 30, 2026recurring
Sep 30, 2025$0.84Oct 31, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
May 17, 20042-for-1forward split